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1 Department of Pediatric Nephrology, Jagiellonian University Medical College, Cracow 30-663, Poland;
katarzyna.zachwieja@gmail.com (K.Z.); dadrozdz@cm-uj.krakow.pl (D.D.);
jacek.a.pietrzyk@gmail.com (J.A.P.)
2 Department of Electronics, Faculty of Computer Science, Electronics and Telecommunications,
AGH University of Science and Technology, Cracow 30-059, Poland; korohoda@agh.edu.pl
3 Department of Pediatric Urology, Jagiellonian University Medical College, Cracow 30-663, Poland;
miwolnic@gmail.com
4 Department of Pediatrics and Nephrology, Medical University of Warsaw, Warsaw, 02-091 Poland;
mmizerskawasiak@op.pl
* Correspondence: mmiklasz@wp.pl or monika.miklaszewska@uj.edu.pl; Tel.: +48-606-262-484
Academic Editor: Harry H.X. Wang
Received: 6 July 2016; Accepted: 26 August 2016; Published: 1 September 2016
Abstract: Myelomeningocele (MMC) results from a failure of normal neural tube fusion in early fetal
development. Retrospective, observational study of medical data of 54 children treated in Pediatric
Nephrology and Urology Clinics for five years was performed. The following data were analyzed:
serum creatinine, eGFR, urine analysis, renal scintigraphy (RS), renal ultrasound, and urodynamics.
Mean age of studied population: 12.3 years, median of eGFR at the beginning and at the end of survey
was 110.25 and 116.5 mL/min/1.73 m2 accordingly. Median of frequency of urinary tract infections
(fUTI): 1.2 episodes/year. In 24 children: low-pressure, in 30 children: high-pressure bladder was
noted. Vesicouretral reflux (VUR) was noted in 23 children (42.6%). fUTI were more common in
high-grade VUR group. High-grade VURs were more common in group of patients with severe renal
damage. At the end of the survey 11.1% children were qualified to higher stages of chronic kidney
disease. Renal parenchyma damage progression in RS was noted in 22.2% children. Positive VUR
history, febrile recurrent UTIs, bladder wall trabeculation, and older age of the patients constitute
risk factors of abnormal renal scans. More than 2.0 febrile, symptomatic UTIs annually increase by
5.6-fold the risk of severe renal parenchyma damage after five years.
Keywords: children; myelomeningocele; chronic kidney disease; urinary tract infection;
renal scintigraphy
1. Introduction
Myelomeningocele (MMC) results from a failure of normal neural tube fusion in early fetal
development. Including spina bifida (SB), it is one of the most common non-chromosomal birth
defects, resulting in a severe damage of numerous organs. In the general population, the incidence of
MMC ranges from 0.3 to 4.5/1000 births [1]. Since, in Poland, great efforts are made to treat all children
born with MMC, such patients constitute a vast number of children seen by pediatric nephrologists,
urologists, and primary care physicians; the affected patients require to be promptly evaluated and
then subjected to long-term follow-up. In the last decade, the prognosis of MMC in children has
dramatically improved, predominantly thanks to the use of superior surgical and shunt implantation
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techniques, combined with preventive renoprotective measures. Thus, the social and economic impact
of neural tube effects is presently substantial.
The abnormal innervation of the bladder detrusor and sphincter is called a neurogenic bladder
(NB). In children with MMC, it causes problems in the bladder storage and emptying functions,
which may lead to high intravesical pressures and recurrent urinary tract infections (rUTIs) that,
in time, will produce renal scarring and progressive deterioration of the upper urinary tract (UUT) [2].
These patients form the largest group requiring nephro-urological management, as chronic kidney
disease (CKD) and renal failure (RF) affecting even 30%–40% of MMC patients are main causes of their
morbidity and mortality [3].
Children with MMC are generally born with normal UUT, but are at a high risk of CKD
secondary to poor bladder dynamics [4]. CKD in those patients is characterized by a highly insidious
onset and course, since the diagnosis of renal impairment in MMC patients is often delayed due to
a misinterpretation of serum creatinine (SCr) levels which, because of their low muscle mass, may mask
kidney failure. For this reason, of vital importance is the ability to monitor their renal function using
an accurate estimated glomerular filtration rate (eGFR) along with visualization and assessment of
renal parenchyma in renal scintigraphy (RS) and ultrasound (US) imaging.
The aim of the study was the evaluation of the occurrence of renal parenchymal damage in RS and
US examinations, as well as assessment of the renal function in children with NB secondary to MMC
during a five-year survey. The secondary objective was to identify the clinical risk factors affecting
those outcomes.
2. Materials and Methods
Sixty-five children treated in our center in the years 2007–2013 were initially selected to participate
in the retrospective, observational study. However, 11 of them did not meet the criteria of the number
and type of the required examinations. Ultimately, a detailed analysis included comprehensive medical
records of 54 children followed up at the Pediatric Nephrology and Urology Clinics, Jagiellonian
University Medical College, for five years. Children that, at the time of inclusion into the study, were
already at the ESKD stage were excluded from the analysis. All of the included children were followed
up at the above clinics for a minimum of 12 months and were treated in keeping with procedures in
force and current medical knowledge. The study group included children above two years of age,
since all of the available pediatric formulas for eGFR calculations were developed for older patients
and, thus, there are no accurate eGFR formulas for children less than two years [5].
The study consisted of the analysis of the below listed procedures, routinely performed in
our center: lab tests including determination of SCr concentration, eGFR calculation based on the
one-marker equation developed by Schwartz et al. [6], general and microbiological urine analysis
(performed regularly, at least once every three months), abdominal ultrasound (performed at least
once every six months); renal urodynamics and ethylenedicysteine (EC) renal scintigraphy—such
examinations and tests were performed once every 18–24 months; the analysis included such children
in whom at least two such examinations were performed during the follow-up. In our center, caregivers
of MMC children are instructed as early as possible to make note and report at the nearest visit in
the clinic each case of febrile (>38.0 ◦C) symptomatic urinary tract infection (UTI) and the employed
therapeutic method. Symptomatic UTI was defined as a positive culture of catheter-extracted urine,
temperature > 38.0 ◦C and pyuria > 20–25 WBC/HPF [7].
Clinical data were entered retrospectively on a regular basis on standardized medical hospital
record sheets at the time of each clinic visit. The information was then extracted between January 2007
and December 2013 for the purpose of this study.
The eGFR value was calculated based on the one-marker equation developed by Schwartz et al. [6].
eGRF calculations included only such SCr values that were determined with the child being in a good
general state, without UTI episodes, or any other clinical situations that negatively affect renal function.
Renal 99mTc ethylenedicysteine scintigraphy (EC RS) is a safe, reliable, and objective method
of assessing both kidney parenchymal damage, and at the same time marker stasis and secretion
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within the pyelocalyceal system (PCS). According to the literature, 99mTc EC RS as compared to 99mTc
DMSA (dimercaptosuccinic acid) RS is an excellent single-modality comprehensive investigational
agent for renal morphology, function and outflow tract evaluation with the added advantages of lower
cost, convenience and low radiation exposure to the patient [8]. The analysis included examinations
performed in the first or second and fourth or fifth year of the follow-up. The following parameters
were evaluated: size and thickness of the parenchyma layer (1: normal; 2: decreased; 3: absence
of active parenchyma layer), signs of kidney parenchymal damage (1: no parenchymal damage;
2: moderate parenchymal damage; 3: severe parenchymal damage), and marker uptake and excretion
(1: proper marker uptake and excretion; 2: decelerated marker uptake and excretion; 3: absent marker
uptake and excretion). Thus, a semi-quantitative analysis of the degree of kidney damage in RS
was performed. The parameters were evaluated separately for each kidney and subsequently added.
In further analysis, the following abbreviations were employed: RS1: no signs of kidney parenchymal
damage in RS; RS2: moderate kidney parenchymal damage in RS; RS3: severe kidney parenchymal
damage in RS (renal scarring).
Urinary tract and kidney ultrasound (US) is a safe, inexpensive, widely available, and convenient
method of evaluating kidney and urinary tract morphology, although it is not an objective way
of assessing an organ. For this reason, in the present study, US images were interpreted by two
appropriately trained and dedicated staff members. The analysis included interpretation of US
examinations performed in the first and last year of the follow-up. The following parameters were
evaluated: kidney parenchymal echogenicity (1: normal echogenicity; 2: increased echogenicity),
corticomedullary differentiation (1: preserved; 2: obliterated), PCS stasis: stasis at the renal pelvis
(1: non-dilated renal pelvises; 2: dilated renal pelvises) and the calyces level (1: non-distended calyces;
2: distended calyces). Thus, a semi-quantitative analysis of the degree of kidney damage in US was
performed. The parameters were evaluated separately for each kidney and subsequently added.
In further analysis, the following abbreviations were employed: US1: no signs of kidney parenchymal
damage in US; US2: moderate kidney parenchymal damage in US; US3: severe kidney parenchymal
damage in US.
The study included children in whom urodynamics was performed at least twice in the first or
second and fourth or fifth year of the survey. While analyzing its results, attention was mainly focused
on intravesical pressure, dividing the bladders into high-pressure and low-pressure (LPP ≥ 40 cm
H2O and LPP < 40 cm H2O, respectively).
All of the children included in the study were prescribed low dose chemiprophylaxis (LDCP)
and clean intermittent catheterization (CIC) to be performed 2–6 times per day for a minimum of
three years of the follow-up, with 21 patients employing a catheter during the night (for a minimum
of two years during the follow-up). Retrograde voiding cystoureterography (RVC) was performed
as clinically indicated. All the analyzed children were subjected to at least one such examination.
Low-grade vesicoureteral reflux (VUR) was termed 1–3 grade VUR, while high-grade VUR was marked
as 4–5 grade VUR.
3. Statistical Analysis
According to the most commonly used parametric description of the study group, to allow for
performing a comparative study, the mean and unbiased standard deviation (SD) estimators were used
to characterize experimental distribution of the data related to age, height, and weight. While height
and weight proved to be Gaussian, according to the Kolmogorow-Smirnov test (threshold 0.1), the age
turned out to be non-Gaussian (threshold 0.05). The test also indicated non-Gaussian distribution
of percentile values for body mass and body height. Thus, for age and specified percentiles we
also provided median and interquartile ranges (IQR), i.e., the range between percentiles 25% and
75%. As some of the investigated numerical data exhibited non-Gaussian distribution, for the sake of
uniformity, all such sets of data were parameterized with the use of the median and IQR. The differences
between distributions were tested with either the Student’s t-test, for data described by mean and
SD, or with the Wilcoxon rank-sum test, for data summarized with the median and IQR. All of the
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data describing the frequency of occurrence were compared with the use of the chi-square test with
Yates correction. In the comparative tests, the indication of significant difference was assumed for
p-values below 0.05. The linear regression model comprising the relationship between the patient age
and the eGFR value was built based on the McPearson correlation coefficient with a relevant p-value.
For selected data, the receiver operating characteristic (ROC curve) analysis was performed with
the smoothed curve obtained after Gaussian modelling. The STATISTICA (STATISTICA, version 10,
StatSoft, Inc., Tulsa, OK, USA) and MATLAB (MATLAB, version 2015a, Mathworks, Inc., Natick, MA,
USA) packages were used for all computations.
4. Results
The detailed characteristics of the studied population are included in Table 1.
Table 1. Clinical characteristics of the studied population (Th-L: thoracolumbar; L-S: lumbosacral; S:
sacral; ACEI: angiotensin-converting-enzyme inhibitors; ARB: angiotensin receptor blockers; CCB:
calcium channel blockers; BB: beta-adrenoceptor blocking agents medications; pts: patients; *: data at
the end of the study).
Variable Studied Population (n = 54)
Female/Male 28 (52%)/26 (48%)
Age (months); Start/End of the study; Mean (SD); (range); Median (IQR) 88.5 (57.3); (24–173)/148.0 (56.7); (84–233); 91.5 (121.0)/151.5 (116.0)
Age (years); Start/End of the study; Mean (SD); (range); Median (IQR) 7.4 (4.8); (2–14.4)/12.3 (4.7); (7–19.4); 7.6 (10.1)/12.6 (9.7)
Body mass (kg) *; Mean (SD) ; (range) 35.9 (16.4); (14–73)
Percentile of body mass *; Mean (SD); (range); Median (IQR) 26.0 (28.3); (3–90); 10.0 (47.0)
Body height (cm) *; Mean (SD); (range) 133.8 (20.3); (98–171)
Percentile of body height *; Mean (SD); (range); Median (IQR) 12.7 (18.9); (3–75); 3.0 (7.0)
Number of UTI/5 years; Median (IQR); (range) 6.0 (8.0); (2–40)
Frequency of UTI/per year; Median (IQR); (range) 1.2 (1.6); (0.4–8.0)
eGFR (mL/min/1.73 m2); (range); Start /End of the study; Median; (IQR); (p) 110.25 (54); (35.3–187.5)/116.5 (28.5); (27–175) (NS)
Ventriculoperitoneal shunt (%) 30 (55.6%)
Level of MMC Th-L: 9 (16.6%); L-S: 34 (63%); S: 11 (20.4%)
Physical activity
Independent ambulation: 7 (13%)
Needs support: 5 (9.2%)
Wheelchair-dependent: 42 (77.8%)
Type of neurogenic bladder
Low-pressure (LPP < 40 cm H2O): 24
(type I (C): 13 (24.1%),
type II (B): 11 (20.3%)
High-Pressure (LPP ≥ 40 cm H2O): 30
(type III (A): 24 (44.4%),
type IV (D): 6 (11.2%).
Vesicoureteral reflux (total) 23 (42.6%)
VUR: Low-grade (1–3) 12 (22.2%)
VUR: High-grade (4–5) 11 (20.4%)
CIC-Median of times a day 4-times
6 times a day 12 patients
5 times a day 12 patients
4 times a day 15 patients
3 times a day 7 patients
2 times a day 8 patients
Overnight catheter 21 patients
Alpha-1 blockers (minimum for 18 months) 18 (33.3%)
Cholinolytics (minimum for 18 months) 36 (66.7%)
Number of children with arterial hypertension 13 (24.1%)
Arterial hypertension treatment ACEI:13; ARB:3; CCB-2; BB:2, Diuretics:2
As it follows from the data in Tables 2 and 3 (that contain the studied parameters and risk factors
of renal injury vs. individual renal damage stages assessed in RS and US respectively), the annual
frequency of symptomatic urinary tract infections (fUTIs) exerted a significant negative effect on both
scintigraphic and ultrasound kidney images after the five-year follow-up. Statistical significance was
shown in the number of fUTI and eGFR when comparing children from the group with severe kidney
damage and patients without or with moderate damage as assessed by both RS and US. There was no
statistical difference between the genders in terms of studied parameters.
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Table 2. Univariate analysis of RS findings in relation to various risk factors.
Studied Variable RS1 (n = 20)(37%)
RS2 (n = 25)
(46.3%)
RS3 (n = 9)
(16.7%)
RS1 + 2 (n = 45)
(83.3%)
RS2 + 3 (n = 34)
(63%)
P: RS1
vs. RS2
P: RS1
vs. RS3
P: RS2
vs. RS3
P: RS1 + 2
vs. RS3
P: RS2 + 3
vs. RS1
Age (months)
Mean (SD) 129.2 (53.3) 150.1 (58.3) 183.8 (45.1) 140.8 (56.5) 159.0 (56.5) NS 0.013 NS 0.037 NS
eGFR (mL/min/
1.73 m2) Median (IQR) 117.4 (27.8) 118.5 (31.0) 67.5 (43.1) 118.0 (29.4) 114.0 (45.0) NS 0.001 0.003 0.001 NS
fUTI Median (IQR) 0.90 (1.00) 1.20 (1.10) 4.00 (5.30) 1.00 (1.25) 1.30 (1.40) NS 0.010 0.012 0.006 NS
VUR (high-grade) (%) 2 (10%) 3 (12%) 6 (66.7%) 5 (11.1%) 9 (26.5%) NS 0.007 0.006 0.001 NS
Bladder
Trabeculation (%) 5 (25%) 14 (56%) 7 (78%) 19 (42.2%) 21 (61.8%) NS 0.024 NS NS 0.020
LPP ≥ 40 cm H2O 8 (40%) 15 (60%) 7 (77.8%) 23 (51.1%) 22 (64.7%) NS NS NS NS NS
CIC ≥ 4 times a day 14 (70%) 18 (72%) 7 (77.8%) 32 (71.1%) 25 (73.5%) NS NS NS NS NS
α1 blockers 7 (35%) 9 (36%) 2 (22.2%) 16 (35.6%) 11 (32.4%) NS NS NS NS NS
Cholinolytics 14 (70%) 17 (68%) 5 (55.6%) 31 (68.9%) 22 (64.7%) NS NS NS NS NS
Both α1 blockers
and Cholinolytics 6 (30%) 6 (24%) 2 (22.2%) 12 (26.7%) 8 (23.5%) NS NS NS NS NS
Neither α1 blockers
nor Cholinolytics 5 (25%) 5 (20%) 4 (44.4%) 10 (22.2%) 9 (26.5%) NS NS NS NS NS
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Table 3. Univariate analysis of US findings in relation to various risk factors.
Studied Variable US1 (n = 21) US2 (n = 18) US3 (n = 15) US1 + 2 (n = 39) US2 + 3 (n = 33) P: US1vs. US2
P: US1
vs. US3
P: US2
vs. US3
P: US1 + 2
vs. US3
P: US2 + 3
vs. US1
Age (months)
Mean (SD) 128.7 (51.8) 141.4 (58.8) 182.9 (47.0) 134.5 (54.8) 160.2 (57.0) NS 0.003 0.035 0.004 0.045
eGFR (mL/min/
1.73 m2) Median (IQR) 119.5 (28.4) 118.2 (30.7) 69.5 (67.6) 118.8 (29.8) 112.0 (45.9) NS 0.004 0.006 0.001 NS
fUTI Median (IQR) 1.00 (1.45) 1.10 (0.80) 2.00 (3.80) 1.00 (1.10) 1.20 (1.65) NS 0.025 0.015 0.008 NS
VUR (high-grade) (%) 1 (4.8%) 4 (22.2%) 6 (40%) 5 (12.8%) 10 (30.3%) NS 0.027 NS NS NS
Bladder
Trabeculation (%) 6 (28.6%) 8 (44.4%) 12 (80%) 14 (35.9%) 20 (60.6%) NS 0.007 NS 0.009 0.044
LPP ≥ 40 cm H2O 10 (47.6%) 9 (50%) 11 (73.3%) 19 (48.7%) 20 (60.6%) NS NS NS NS NS
CIC ≥ 4 times a day 13 (61.9%) 13 (72.2%) 13 (86.7%) 26 (66.7%) 26 (78.8%) NS NS NS NS NS
α1 blockers 9 (42.9%) 7 (38.9%) 2 (13.3%) 16 (41%) 9 (27.3%) NS NS NS NS NS
Cholinolytics 13 (61.9%) 13 (72.2%) 10 (66.7%) 26 (66.7%) 23 (69.7%) NS NS NS NS NS
Both α1 blockers
and Cholinolytics 7 (33.3%) 5 (27.8%) 2 (13.3%) 12 (30.8%) 7 (21.2%) NS NS NS NS NS
Neither α1 blockers
nor Cholinolytics 6 (28.6%) 3 (16.7%) 5 (33.3%) 9 (23.1%) 8 (24.2%) NS NS NS NS NS
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Children with severe kidney parenchymal damage were also significantly older as compared to
children without or with moderate damage (RS: 129.2 vs. 183.8 (months) (RS1 vs. 3); 140.8 vs. 183.8
(months) (RS1 + 2 vs. 3)). Moreover, a negative, average, significant correlation was noted between the
age of the patients expressed in months and kidney function expressed as the eGFR value (r = −0.444;
p = 0.008) (Figure 1). No correlation was observed, however, between the age of the patients and fUTI.
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Additionally, high VUR values in RS assessment of kidney parenchyma function was significantly
more common in the group with severe damage as compared to children without or with moderate
damage (10% vs. 66.7% (RS1 vs. 3); 12% vs. 66.7% (RS2 vs. 3); 11.1% vs. 66.7% (RS1 + 2 vs. 3)). In case
of US assessment, significance was noted solely between the group without signs of damage and
children with severe damage.
On the other hand, bladder wall trabeculation was significantly more common in the group with
a severe or moderate degree of renal parenchymal damage as compared to patients without such
damage (25% vs. 78% (RS1 vs. 3); 25% vs. 61.8% (RS1 vs. RS2 + 3)).
However, no significant differences were noted in both RS and US imaging in the percentage
of high-pressure bladders, frequency of CIC employment (≥ or <4 times a day), or type of used
pharmacotherapy affecting the bladder motility.
As it follows from the analysis of the ROC curve for fUTI after five years of the follow-up,
with a cut-off value of fUTI of 2.0 annually (at 64.6% sensitivity, 83.5% specificity and 80%
AUROC—what denotes a good prognostic value of the parameter), the risk of severe kidney damage
in RS (RS3) increased 5.6-fold (Figure 2).
At the end of follow-up, deterioration of eGFR values was noted in 11 (30.4%) patients, of
whom six (11.1%) children were qualified to higher CKD stages. Progression of renal parenchymal
damage in RS imaging was seen in 12 (22.2%) children (10 showed RS1 to RS2 progression, 2—RS2
to RS3 progression); while US demonstrated such a progression in 25 (46.3%) children (14—US1 to
US2 progression, 11—US2 to US3 progression). The correlation between the degree of kidney damage
in RS and US imaging at the beginning and end of the follow-up was 76% and 74.1%, respectively.
As it follows from the above analysis, in the studied population, severe kidney damage was
predominantly affected by an older age of the patient (both in case of imaging and renal function),
higher fUTI frequency (especially fUTI > 2.0), high VUR values and the presence of bladder
trabeculation indicating long-term bladder outlet obstruction. No effect on the degree of kidney
Int. J. Environ. Res. Public Health 2016, 13, 876 8 of 13
damage assessed in RS or US imaging was observed in case of CIC frequency, employment of
alpha-lytic and cholinergic medications, and type of neurogenic bladder.Int. J. Environ. Res. Public Health 2016, 13, 876 9 of 14 
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fUTI VUR: No(n = 31)
VUR:
High-Grade
(n = 11)
VUR: No +
Low-Grade
(n = 43)
VUR: Low +
High-Grade
(n = 23)
P1: VUR:
No vs. Low +
High-Grade
P2:VUR No +
Low-Grade vs.
High-Grade
fUTI Median
(IQR) 1.0 (0.9) 2.2 (3.9) 1.0 (1.4) 2.0 (2.1) 0.033 0.043
No significance was noted in fUTI in the groups with low vs. high-pressure bladders (median:
1.0 vs. 1.2) and in the groups employing CIC <4 times vs. ≥4 times/day (median: 0.8 vs. 1.2).
Thus, no effect was observed of the type of neurogenic bladder and CIC frequency on the frequency of
symptomatic fUTI.
Significant bacteriuria was noted in each child at least once at any time of the follow-up.
However, only 33.3% cases of such significant bacteriuria were qualified as symptomatic UTI and
required treatment with antibiotics or full-dose chemotherapeutic agents. Frequency of particular
etiological agents of UTIs are presented in Table 5. Both the type of bacteria and their incidence in the
population of MMC children as a factor in the etiology of symptomatic UTI were comparable to data
from the literature [4,9].
Low dose chemiprophylaxis (LDCP) was employed in all of the children. In total, 121 treatment
courses were used, including furazidin therapy in 52 (43%), trimethoprim and sulfamethoxazole in
33 (27.3%), herbal preparations in 16 (13.2%), bladder lavage (1% neomycin/gentamycin) in 10 (8.3%),
fluoroquinolones (cipro-/norfloxacin) in seven (5.8%), and oral Escherichia coli vaccine in three (2.4%)
children. One type of treatment during 5 years of the follow-up was employed in 15 (27.8%) children;
two types of medications in 21 (38.9%); three types in 11 (20.4%); four types in four (7.4%); and five
types in three (5.5%) patients.
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Symptomatic UTI was most commonly treated with cefuroxime (29.3%), ceftazidime (23.3%),
amoxicillin with clavulanic acid (10.3%), and ciprofloxacin (9.5%). Full doses of furazidin (4.3%),
meropenem (3.4%), full doses of trimethoprim and sulfamethoxazole (2.6%), piperacillin with
tazobactam (2.6%), and vancomycin (2.6%) were employed more rarely. Symptomatic UTI of
fungal etiology was most frequently treated with azoles (fluconazole, ketoconazole—10.3%) and
caspofungin (1.8%).
Table 5. Frequency of particular etiological agents of UTI in the studied population.
Ethiological Agent Percentage of UTI (%)
Enterobacteriaceae family (Gram negative)
Escherichia coli 36.9
Klebsiella spp. (pneumoniae, oxytoca) 16.8
Proteus spp. (vulgaris, mirabilis) 4.0
Enterobacter spp. (cloacae, agglomerans, hafniae) 3.0
Citrobacter (koseri, freundii) 1.7
Morganella morganii 1.3
Serratia marcescens 0.7
Non-Enterobacteriaceae family (Gram negative)
Pseudomonas spp. (aeruginosa, putida) 21.6
Acinetobacter baumanii 1.3
Stenotrophomonas maltophilia 0.7
Cocci (Gram positive)
Enterococcus spp. (faecium, faecalis) 5.1
Staphylococcus aureus 1.3
Yeasts
Candida spp. (albicans, parapsilosis, tropicalis, krusei) 5.6
5. Discussion
At birth, most newborns with MMC have a normal UUT. However, the majority will develop
deterioration of renal function and bladder wall changes, which start within the first six months of
life [2]. Two main goals in the nephro-urological management of MMC patients, which are preserving
renal function and achieving social continence, are sometimes mutually exclusive since, for the UUT,
sometimes it is superior to achieve a “wet but safe” rather than a “dry but unsafe” bladder. Therefore,
the management of these children must be strongly focused on prevention of renal scarring and its
progression to CKD.
The incidence of renal scarring in RS in the current study was 16.7%, which is quite coherent with
numbers found in the literature in similar groups of patients, as several reports described scarring rates
of 12.8%–28.6% [2,10,11]. Disorders of the lower urinary tract in MMC patients cause secondary VUR,
and ultimately renal parenchymal damage with the contribution of UTI. Hence, several factors may
contribute to the severity of renal scarring. In the current study, among others, these factors included
high-grade VURs (significantly more often noted in RS3 and US3 patients), a higher frequency of
symptomatic, febrile UTI (especially exceeding 2.0 episodes per year), bladder wall trabeculation,
and older age of the patient. It was also noted that a higher number of fUTI was associated with
high-grade VUR. In the literature, there are studies confirming that the severity of VUR and febrile
recurrent UTIs affects the likelihood of renal scarring and renal deterioration [12,13]. Moreover, there
are reports that the chance of cortical damage determined by RS tends to increase with age [14].
EC RS is a useful tool in determining the loss of renal parenchyma in MMC children with febrile,
rUTIs and high-grade VUR. However, in case of the impossibility of performing RS, US imaging as
cheap, fast, and easily accessible is also acceptable for first-line renal parenchyma assessment since,
in the present investigation, the correlation between RS and US at the beginning and the end of the
study was as high as 76% and 74.1%, respectively.
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UTIs are a common source of morbidity among children with MMC; however, they persist as
one of the most difficult complications to diagnose, treat, and prevent in those patients. Appropriate
specimen collection is of a paramount importance and UTI cannot be diagnosed based on a culture and
urinalysis alone in the absence of clinical symptoms. Hence, in the literature, the reported incidence
of UTI in MMC patients is variable. It is estimated that the overall rate of UTI in patients with NB is
0.3 to 2.5 episodes per patient per year [15]. In the current study, the median of the number of UTI
was 6.0 per patient in the 5-year follow-up, which in turn renders the frequency of UTI (fUTI) equal
to 1.2 episodes per patient per year. Other studies demonstrated that the annual incidence of UTI in
patients with NB ranged from 20% [16] to 36.4% [17].
Febrile, symptomatic UTIs and VURs are closely linked with each other and are strong risk factors
of renal scarring and CKD progression. In the current study, VUR was noted in 42% of the patients
and the percentage is quite comparable to the values reported in the literature on the subject. In the
present study, the median of fUTI was statistically significantly higher in the high-grade VUR group
vs. the group without VUR or with low-grade VUR, and in the patients with VUR of any grade vs.
the children without this complication. The incidence of VUR in the MMC populations reported
in particular studies ranges from 26.8%–50% [18]. The authors conclude that renal scars in MMC
populations are associated with febrile, rUTIs, high-grade VUR, presence of bladder wall trabeculation,
and older patient age. Seki et al. [19], agreeably with the current results, also noted that the presence
of VUR was directly correlated with febrile UTI, while febrile UTI was a risk factor for renal scarring
in MMC children. Furthermore, bladder wall trabeculation was also recognized in the literature as
an independent risk factor for renal parenchymal damage and scarring [10].
According to the literature, asymptomatic bacteriuria not requiring any treatment is noted
in 60%–85% of MMC patients, whereas only 21%–35% of them become symptomatic and receive
pharmacological treatment [9,20]. In the current study, the percentage of symptomatic UTIs amounted
to 33.3%, whereas asymptomatic bacteriuria at any time during the follow-up was noted in every
patient, what may be associated with 100% of the patients being on CIC.
The main goal of CIC is the protection of renal parenchyma by decreasing the intravesical pressure
and preventing VUR. CIC, along with anticholinergics and α1-selective blockers, are commonly used
treatment modalities in MMC populations worldwide. The percentage of CIC in the literature is
quite variable and—to quote various authors—its number varies from 63.9%–100% of patients [3,21],
whereas anticholinergics due to high bladder pressures or urinary incontinence are used according
to the literature in 50%–56.1% of NB patients [15,22]. Despite their high popularity, in many studies
they did not prove to be an effective treatment tool against renal deterioration in MMC patients [21,23].
Similarly, in the current study, anticholinergics, α1-selective alpha blockers, and CIC did not favorably
affect the degree of renal parenchymal damage assessed in RS or US. However, considering CIC,
it must be noted that this procedure during the daytime was regularly used in all our patients
which, on the one hand, might have induced the strongest positive impact on renal parenchyma
protection, but on the other, simultaneously happened to become a cause of a 100% incidence of
asymptomatic bacteriuria in this population. Since CIC administration increases the frequency of
significant bacteriuria, it simultaneously decreases the frequency of symptomatic UTI, acting as a potent
renoprotective measure [24,25].
In a European survey, 85% of centers rarely prescribed LDCP to MMC children when not on CIC,
but prescribed it in nearly 50% of children on CIC [22]. In the current study, all the children were on
CIC and all were receiving LDCP. Studies examining the effect of LDCP on symptomatic UTI reported
divergent results, with a reduction of the rate in some [26] and a higher number of infections in other
cohorts [27]. Apart from that, many studies also showed that more resistant organisms may be selected
out by long-term LDCP [26]. Therefore, we realize that the attitude towards long-term LDCP in our
center should be reconsidered with respect to prevalence and duration of its administration.
Despite a great progress in nephro-urological management of MMC patients, renal failure still
remains life-threatening in this population. Renal function deterioration at various time frames of
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a long-term surveillance reported in the literature was noted, being in the ranges from 10.7%–18% [3,10]
of patients, while end-stage kidney disease (ESKD) in this population was observed in the ranges from
7.5%–15% [4,28] of patients. The problem of CKD-ESKD underestimation may arise from the fact that
monitoring renal function in MMC patients is particularly challenging due to a reduced muscle mass
and the degree of immobility. Consequently, weight cannot be used in these patients as an indicator of
lean body mass. Therefore, in MMC patients, SCr is no longer an accurate marker of renal function.
Consequently, normal SCr does not exclude renal dysfunction in those patients and furthermore, renal
function evaluation by SCr-based equations (like Schwartz et al. [6]) is overestimated. Similarly, in the
current study, the medians of percentiles of height (12.7) and body mass (26.0) demonstrated that
eGFR in this population should not be assessed using the same equations as in case of healthy children.
Hence, in the present study, the outwardly median of eGFR seemed to be within normal limits and was
not statistically significant when comparing the beginning and the end of the study. However, after the
five-year follow-up, in particular cases, eGFR deterioration was noted in 11 (30.4%) patients, whereas
six (11.1%) were qualified to higher CKD stages. Furthermore, renal parenchyma deterioration in
both RS and US imaging was noted in 12 (22.2%) and 25 (46.3%) children, respectively. These results
support the fact that firstly, we must neither rely on eGFR results only, nor asses the whole population
in general, but also we must pay attention to renal imaging techniques while evaluating renal function
in MMC patients. Moreover, a negative, statistically significant effect exerted on eGFR values was
noted in case of patient age after the five-year survey.
The authors are aware of the limitations of this study. It was a retrospective, observational,
single-center study, wherein all the patients were taking LDCP. Notwithstanding, during the five-year
study, all the essential data were minutely collected on a current basis and the entire patient
management proceeded as clinically indicated. We also realize that eGFR values calculated according
to the Schwartz et al. [6] equation are overestimated. Nevertheless, in this study we concentrated on
relative eGFR changes between the beginning and end of the evaluation period, hence, the bias due
to eGFR overestimation did not significantly affect the final results. It seems that for a more detailed
renal function evaluation in this sort of population, only a prospective study including cystatin C and
iohexol assessment may yield more precise results.
The objective of the present study was increasing our understanding of risk factors involved
in renal deterioration in MMC patients. It was found that preventing febrile UTI, high-grade
VUR, and bladder wall trabeculation by ensuring free urine outflow may reduce the risk of renal
parenchymal damage.
To prevent renal damage, nephro-urological highly specialized management of NB should start
right in the neonatal period. For optimal treatment results, a multidisciplinary approach is needed,
with collaboration of members from numerous medical specialties. Compliance with long-term,
wearisome treatment is suggested to be another important factor constituting a challenge for the
patients and caregivers.
6. Conclusions
In MMC patients, the presence of high-grade VUR is correlated with febrile UTIs. In turn,
a positive VUR history, febrile rUTIs, bladder wall trabeculation and older patient age constitute risk
factors of abnormal renal scans at the end of a 5 year survey in this population. More than 2.0 febrile,
symptomatic UTIs annually increase by 5.6-fold the risk of severe renal parenchymal damage assessed
in RS at the end of five-year follow-up. Due to the lack of reliability of SCr in MMC patients, repeated
EC or DMSA RS for early detection of renal scarring are strongly recommended. However, the US
imaging technique is also acceptable for general renal parenchyma assessment.
To answer the question formulated in title of this paper, firstly: the administration of LDCP
might be limited only to children with a high risk of renal cortical scarring in RS; secondly: it might
be considered that renal function in this population would be assessed by the Cystatin C and
iohexol method.
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Abbreviations
The following abbreviations are used in this manuscript:
MMC Myelomeningocele
NB Neurogenic Bladder
SB Spina Bifida
rUTI recurrent Urinary Tract Infections
VUR Vesicoureteral Reflux
ESKD End Stage Kidney Disease
CKD Chronic Kidney Disease
LDCP Low Dose Chemoprophylaxis
LPP Leak Point Pressure
UUT Upper Urinary Tract
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Alpha-Blockers in the Treatment of Children with Neurogenic Bladder Dysfunction—Preliminary Findings.
Int. J. Environ. Res. Public Health 2016, 13, 321–328. [CrossRef] [PubMed]
26. Schlager, T.A.; Anderson, S.; Trudell, J.; Hendley, J.O. Nitrofurantoin prophylaxis for bacteriuria and urinary
tract infection in children with neurogenic bladder on intermittent catheterization. J. Pediatr. 1998, 132,
704–708. [CrossRef]
27. Woodhouse, C.R.J. Myelomeningocele in young adults. BJU Int. 2005, 95, 223–230. [CrossRef] [PubMed]
28. Lawrenson, R.; Wyndaele, J.J.; Vlachonikolis, I.; Farmer, C.; Glickman, S. Renal failure in patients with
neurogenic lower urinary tract dysfunction. Neuroepidemiology 2001, 20, 138–143. [CrossRef] [PubMed]
© 2016 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC-BY) license (http://creativecommons.org/licenses/by/4.0/).
